Basecamp Research Raises $140M Series C

Basecamp Research, with dual headquarters in London and Boston, is a frontier AI company developing AI-designed medicines. The company recently secured $140 million in Series C financing to train its next generation of EDEN models and advance its pipeline of AI-designed therapeutics toward clinical development.

Investors

The oversubscribed round was led by S32, with participation from Anthropic’s Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures. Additional investment came from senior leaders across the pharmaceutical, biotechnology, and global industry sectors, including André Hoffmann, Vice-Chairman of Roche.

Basecamp Research Use of Funds

Basecamp Research intends to use the capital to train a new generation of its EDEN foundation models and advance a pipeline of AI-designed therapeutics, with a primary focus on in vivo cell therapy. The funding will also support the expansion of the company's pharmaceutical partnerships.

About Basecamp Research

Founded to develop cures for diseases currently deemed incurable, Basecamp Research specializes in AI-designed therapeutics. The company combines frontier AI models trained on its proprietary biological data, known as the Trillion Gene Atlas, with technology for writing DNA sequences directly into cells to reprogram the body for repair.

Funding Details

Company Website: https://basecamp-research.com

Company: Basecamp Research
Raised: $140M
Round: Series C
Funding Date: September 23, 2026
Lead Investor: S32
Additional Investors: Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, True Ventures
Software Category: AI/Biotech
Source: https://www.prnewswire.com/news-releases/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics-302887620.html